KfW Group, a German state-owned development bank, GlaxoSmithKline, a pharmaceutical company and Qatar Investment Authority, led a $640 financing round in CureVac, a clinical-stage biopharmaceutical company. The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau with $343m and GSK with $171m as well as additional new equity investments from Qatar Investment Authority and a group of existing and new investors with approximately $126m. “We are delighted to partner with GSK. With this collaboration, we are gaining a world-class partner whose expertise and global footprint will allow us to further develop and translate the value of our platform into potential products for the world,” Franz-Werner Haas CureVac CEO.